Guideline-Driven Management of Hypertension: An Evidence-Based Update.
Carey RM, Wright JT Jr, Taler SJ, Whelton PK.
Circ Res. 2021 Apr 2;128(7):827-846. doi: 10.1161/CIRCRESAHA.121.318083. Epub 2021 Apr 1.
Clinical Management of Primary Aldosteronism: An Update.
Rossi GP, Rossi FB, Guarnieri C, Rossitto G, Seccia TM.
Hypertension. 2024 Sep;81(9):1845-1856. doi: 10.1161/HYPERTENSIONAHA.124.22642. Epub 2024 Jul 24.
The Effect of Aldosterone on Cardiorenal and Metabolic Systems.
Otsuka H, Abe M, Kobayashi H.
Int J Mol Sci. 2023 Mar 11;24(6):5370. doi: 10.3390/ijms24065370.
Screening for primary aldosteronism is underutilised in patients with chronic kidney disease.
Chauhan K, Schachna E, Libianto R, Ryan J, Hutton H, Fuller PJ, Wilson S, Kerr PG, Yang J.
J Nephrol. 2022 Jul;35(6):1667-1677. doi: 10.1007/s40620-022-01267-3. Epub 2022 Feb 23.
Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation.
Wang CA, Lai HW, Chen JY, Wang WJ, Lin LC, Chiu YL, Cheng CY, Wu VC.
Nat Commun. 2025 Oct 31;16(1):9641. doi: 10.1038/s41467-025-64640-3.
Primary Aldosteronism in Chronic Kidney Disease: Blood Pressure Control and Kidney and Cardiovascular Outcomes After Surgical Versus Medical Management.
Cohen DL, Wachtel H, Vaidya A, Hundemer GL, Tezuka Y, Davio A, Turcu AF, Cohen JB.
Hypertension. 2023 Oct;80(10):2187-2195. doi: 10.1161/HYPERTENSIONAHA.123.21474. Epub 2023 Aug 18.
Renin-independent aldosteronism and chronic kidney disease in diabetes: Observational and Mendelian randomization analyses.
Hu J, Chen X, Luo Y, Yang J, Zeng Q, Luo W, Shu X, Cheng Q, Gong L, Wang Z, Li Q, Yang S.
Metabolism. 2023 Aug;145:155593. doi: 10.1016/j.metabol.2023.155593. Epub 2023 May 25.
Evaluation and Management of Resistant Hypertension: Core Curriculum 2024.
Cluett JL, William JH.
Am J Kidney Dis. 2024 Sep;84(3):374-387. doi: 10.1053/j.ajkd.2024.04.009. Epub 2024 Jul 20.
Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
Dogra S, Shah S, Gitzel L, Pusukur B, Sood A, Vyas AV, Gupta R.
Curr Probl Cardiol. 2023 Nov;48(11):101918. doi: 10.1016/j.cpcardiol.2023.101918. Epub 2023 Jul 2.
Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
Lv R, Xu L, Che L, Liu S, Wang Y, Dong B.
Front Endocrinol (Lausanne). 2023 Feb 13;14:1125693. doi: 10.3389/fendo.2023.1125693. eCollection 2023.
